OncLive TV

Syma Iqbal, MD, discusses the emergence of checkpoint inhibitors in upper gastrointestinal cancers.

Ashley E. Rosko, MD, discusses disparities within clinical trials in multiple myeloma.

Ulka Nitin Vaishampayan, MBBS, discusses future directions for second-line treatment in urothelial cancer.

Andrew M. Evens, DO, MSc, discusses highlights from the 2021 RWJ Annual Clinical and Practice Research Summit.

Christian S. Hinrichs, MD, discusses unmet needs with cellular therapies in metastatic epithelial cancer.

Jyoti Malhotra, MD, MPH, discusses challenges with precision medicine in advanced solid tumors.

Manojkumar Bupathi, MD, MS, discusses considerations for second-line treatment sequencing in clear cell renal cell carcinoma.

Phillip L. Palmbos, MD, PhD, discusses remaining questions in metastatic urothelial carcinoma.

Sarah S. Lee, MD, discusses definition criteria for smoldering multiple myeloma.

Matthew Galsky, MD, discusses key developments in the standard-of-care treatment of patients with metastatic or advanced urothelial cancer.

Steven J. Cohen, MD, discusses the importance of obtaining an adequate tissue sample for molecular testing in gastrointestinal cancers.

Shridar Ganesan, MD, PhD, discusses improvements in precision medicine and the need to enroll patients with different molecular subtypes into specifically designed clinical trials.

Howard S. Hochster, MD, FACP, discusses treatment considerations for patients with HER2-positive gastric cancer.

Breelyn Wilky, MD, discusses the diagnosis and management of desmoid tumors.

Carla Falkson, MBChB, MMed, MD, discusses opportunities for de-escalating therapy in patients with HER2-positive breast cancer. 

Toni K. Choueiri, MD, discusses the FDA approval of adjuvant pembrolizumab in renal cell carcinoma.

Myrto Moutafi, MD, MSc, discusses the results of a study evaluating biomarkers of resistance in non–small cell lung cancer.

Caroline Nebhan, MD, PhD, discusses the efficacy of checkpoint inhibitors in older patients with cancer.

Ruben A. Mesa, MD, discusses strategies for navigating the expanding paradigm of JAK inhibitors in myeloproliferative neoplasms.

Hans Wildiers, MD, medical oncologist, Department of Medical Oncology, full professor, Faculty of Medicine, member, Laboratory of Experimental Oncology, University Hospital Leuven, Leuven, Belgium, discusses the final results of the phase 2b AIPAC trial (NCT02614833) in hormone receptor (HR)–positive, HER2-negative metastatic breast cancer.

Jonathan D. Cheng, MD, discusses advances with immunotherapy-based combinations in oncology.

Alexandra Stefanovic, MD, discusses the emergence of umbralisib in marginal zone lymphoma and follicular lymphoma.

Brian Ramnaraign, MD, discusses current first-line treatment guidelines for patients with metastatic renal cell carcinoma. 

Bassel El-Rayes, MD, discusses the efficacy of tidutamab in advanced neuroendocrine tumors.

Pamela Kunz, MD, discusses the importance of tailoring treatments to individual patients with neuroendocrine tumors.

Deborah L. Toppmeyer, MD, discusses the utility of clinical trials evaluating de-escalated treatment approaches in HER2-positive breast cancer.

Saum Ghodoussipour, MD, discusses ongoing trials in non–muscle invasive bladder cancer.

Kathleen C. Toomey, medical oncologist, discusses the importance of clinical trials evaluating de-escalated treatment strategies in HER2-positive breast cancer.

Mansi R. Shah, MD, discusses ongoing research examining the CAR T-cell therapy ciltacabtagene autoleucel for the treatment of patients with relapsed or refractory multiple myeloma.

Dennis Cooper, MD, sheds light on the novel therapeutic regimens available to patients with multiple myeloma.